A fast-acting compound that appears to improve cognitive function impairments in mice similar to those found in patients with progressive Alzheimer's disease has been identified by scientists at Wake Forest University School of Medicine and the Vanderbilt University Medical Center Program in Drug Discovery. Researchers hope to one day replicate the result in humans.
The compound -- benzylquinolone carboxylic acid (BWCA) -- has also been shown in previous rodent studies to lessen the occurrence and severity of the behavioral disturbances often symptomatic of Alzheimer's, such as hallucinations, delusions, paranoia and outbursts.
"That makes this compound somewhat novel," said Michelle M. Nicolle, PhD, an associate professor of gerontology at Wake Forest and co-researcher on the study, published recently in the Journal of Neuroscience. "We wanted to see if this very specific acting compound was able to change the way the brain works and whether or not if improved memory in our 'Alzheimer's mice,'